Korro Bio posts Q2 2026 results, highlights KRRO-121 and new candidate KRRO-111

Korro Bio, Inc. reported second quarter 2026 financial results and a corporate update on August 6, 2026. The company said KRRO-121, described as a potential first-in-class treatment for hyperammonemia, remains on track to begin its first-in-human clinical trial in the second half of 2026.¹ Korro also said it received Orphan Drug Designation from the European Medicines Agency for KRRO-121 in patients with urea cycle disorders.¹

The company nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD). In preclinical work, Korro said the compound was over 90% efficient at editing the SERPINA1 transcript in vivo, which translated to roughly 90% repaired, functional AAT protein in plasma in a mouse model of AATD.¹

On finances, Korro reported cash, cash equivalents and marketable securities of $137.9 million as of June 30, 2026, up from $85.2 million as of December 31, 2025.¹ The company said this is expected to fund operations into the second half of 2028.¹ There was no collaboration revenue in the quarter, versus $1.5 million a year earlier, reflecting a 12-month pause of the Novo Nordisk collaboration agreed in November 2025.¹ R&D expenses fell to $13.6 million from $20.1 million a year earlier¹, and net loss was $18.9 million, compared with $25.8 million in the same quarter of 2025.¹

Separately, an accompanying Form 8-K disclosed that on August 5, 2026, Korro entered an exchange agreement with Venrock Healthcare Capital Partners entities, under which Venrock surrendered 1,000,000 shares of common stock in exchange for pre-funded warrants to purchase the same number of shares at a $0.001 exercise price with no expiration date.¹